Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
disease-modifying antirheumatic drug
|
| gptkbp:abbreviation |
tsDMARDs
|
| gptkbp:class |
Janus kinase inhibitors
|
| gptkbp:distinctiveFeature |
gptkb:biologic_DMARDs
gptkb:conventional_synthetic_DMARDs |
| gptkbp:example |
gptkb:tofacitinib
gptkb:upadacitinib gptkb:baricitinib gptkb:filgotinib |
| https://www.w3.org/2000/01/rdf-schema#label |
targeted synthetic DMARDs
|
| gptkbp:mechanismOfAction |
target specific molecular pathways
|
| gptkbp:regulates |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
elevated liver enzymes
blood clots increased risk of infections |
| gptkbp:target |
signal transduction pathways
Janus kinase pathway |
| gptkbp:usedFor |
gptkb:psoriatic_arthritis
rheumatoid arthritis ankylosing spondylitis |
| gptkbp:bfsParent |
gptkb:DMARDs
|
| gptkbp:bfsLayer |
7
|